• 1
    Sun Y, Keay S, De Deyne PG, Chai TC. Augmented stretch activated adenosine triphosphate release from bladder urothelial cells in patients with interstitial cystitis. J Urol 2001; 166: 19516.
  • 2
    Chuang YC. Basic science research on bladder and urine markers for interstitial cystitis-current and future directions. Incont Pelvic Floor Dysfunct 2008; 2: 456.
  • 3
    Lanteri-Minet M, Bon K, de Pommery J, Michiels JF, Menetrey D. Cyclophosphamide cystitis as a model of visceral pain in rats: model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins. Exp Brain Res 1995; 105: 22032.
  • 4
    Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 20459.
  • 5
    Eichel L, Scheidweiler K, Kost J et al. Assessment of murine bladder permeability with fluorescein: validation with cyclophosphamide and protamine. Urology 2001; 58: 113–18.
  • 6
    Wood R, Eichel L, Messing EM, Schwarz E. Automated noninvasive measurement of cyclophosphamide-induced changes in murine voiding frequency and volume. J Urol 2001; 165: 6539.
  • 7
    Andersson KE. Overactive bladder-pharmacological aspects. Scand J Urol Nephrol Suppl 2002; 210: 7281.
  • 8
    Birder LA, Ruan HZ, Chopra B et al. Alterations in P2X and P2Y purinergic receptor expression in urinary bladder from normal cats and cats with interstitial cystitis. Am J Physiol Renal Physiol 2004; 287: 108491.
  • 9
    Smith CP, Vemulakonda VM, Kiss S, Boone TB, Somogyi GT. Enhanced ATP release from rat bladder urothelium during chronic bladder inflammation: effect of botulinum toxin A. Neurochem Int 2005; 47: 2917.
  • 10
    Tempest HV, Dixon AK, Turner WH, Elneil S, Sellers LA, Ferguson DR. P2X2 and P2X3 receptor expression in human bladder urothelium and changes in interstitial cystitis. BJU Int 2004; 93: 13448.
  • 11
    Giglio D, Ryberg AT, To K, Delbro DS, Tobin G. Altered muscarinic receptor subtype expression and functional responses in cyclophosphamide induced cystitis in rats. Auton Neurosci 2005; 122: 920.
  • 12
    Kageyama A, Fujino T, Taki Y et al. Alteration of muscarinic and purinergic receptors in urinary bladder of rats with cyclophosphamide-induced interstitial cystitis. Neurosci Lett 2008; 436: 814.
  • 13
    Yoshida A, Kageyama A, Fujino T, Nozawa Y, Yamada S. Loss of muscarinic and purinergic receptors in urinary bladder of rats with hydrochloric acid-induced cystitis. Urology 2010; 76: 712.
  • 14
    Saini R, Gonzalez RR, Te AE. Chronic pelvic pain syndrome and the overactive bladder: the inflammatory link. Curr Urol Rep 2008; 9: 314–19.
  • 15
    Smaldone MC, Vodovotz Y, Tyagi V et al. Multiplex analysis of urinary cytokine levels in rat model of cyclophosphamide-induced cystitis. Urology 2009; 73: 4216.
  • 16
    Sakumoto M, Matsumoto T, Mochida O, Takahashi K, Sakuma S, Kumazawa J. Urinary concentrations of cytokines in patients with pyelonephritis and cystitis. J Infect Chemother 1998; 4: 247.
  • 17
    Avins AL, Bent S, Staccone S et al. A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008; 16: 14754.
  • 18
    Barnes PM, Powell GE, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; 343: 120.
  • 19
    Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada S. Isolation and pharmacological characterization of fatty acids from saw palmetto extract. Anal Sci 2009; 25: 5537.
  • 20
    Iehle C, Delos S, Guirou O, Tate R, Raynaud JP, Martin PM. Human prostatic steroid 5 alpha-reductase isoforms-a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 1995; 54: 2739.
  • 21
    Sultan C, Terraza A, Devillier C et al. Inhibition of androgen metabolism and binding by a liposterolic extract of “Serenoa repens B” in human foreskin fibroblasts. J Steroid Biochem 1984; 20: 515–19.
  • 22
    Paubert-Braquet M, Cousse H, Raynaud JP, Mencia-Huerta JM, Braquet P. Effect of the lipidosterolic extract of Serenoa repens (Permixon) and its major components on basic fibroblast growth factor-induced proliferation of cultures of human prostate biopsies. Eur Urol 1998; 33: 3407.
  • 23
    Goepel M, Hecker U, Krege S, Rubben H, Michel MC. Saw palmetto extracts potently and noncompetitively inhibit human α1-adrenoceptors in vitro. Prostate 1999; 38: 20815.
  • 24
    Koch E. Extracts from fruits of saw palmetto (Sabal serrulata) and roots of stinging nettle (Urtica dioica): viable alternatives in the medical treatment of benign prostatic hyperplasia and associated lower urinary tracts symptoms. Planta Med 2001; 67: 489500.
  • 25
    Gutierrez M, García de Boto MJ, Cantabrana B, Hidalgo A. Mechanisms involved in the spasmolytic effect of extracts from sabal serrulata fruit on smooth muscle. Gen Pharm 1996; 27: 1716.
  • 26
    Oki T, Suzuki M, Nishioka Y, Yasuda A, Umegaki K, Yamada S. Effects of saw palmetto extract on micturition reflex of rats and its autonomic receptor binding activity. J Urol 2005; 173: 13959.
  • 27
    Suzuki M, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada S. Muscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tract. Urology 2007; 69: 121620.
  • 28
    Suzuki M, Ito Y, Fujino T et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin 2009; 30: 27181.
  • 29
    Chow YC, Yang S, Huang CJ et al. Epinephrine promotes hemostasis in rats with cyclophosphamide-induced hemorrhagic cystitis. Urology 2006; 67: 63641.
  • 30
    Mok MHS, Knight GE, Andrews PLR, Hoyle CHV, Burnstock G. The effects of cyclophosphamide on neurotransmission in the urinary bladder of Suncus murinus, the house musk shrew. J Auton Nerv Syst 2000; 80: 1306.
  • 31
    Yamada S, Isogai M, Okudaira H, Hayashi E. Regional adaptation of muscarinic receptors and choline uptake in brain following repeated administration of diisopropylfluorophosphate and atropine. Brain Res 1983; 268: 31520.
  • 32
    Chang H, Hanawa H, Yoshida T et al. Alteration of IL-17 related protein expressions in experimental autoimmune myocarditis and inhibition of IL-17 by IL-10-Ig fusion gene transfer. Circ J 2008; 72: 813–19.
  • 33
    Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology 2001; 57: 4755.
  • 34
    Mitropoulos D, Kyroudi A, Zervas A et al. In vivo effect of the lipido-sterolic extract of Serenoa repens (Permixon) on mast cell accumulation and glandular epithelium trophism in the rat prostate. World J Urol 2002; 19: 45761.
  • 35
    Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H. Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung 1992; 42: 54751.
  • 36
    Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, Lopez Farre A. BPH and inflammation: pharmacological effects of permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol 2003; 44: 54955.
  • 37
    Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int 2012; 110: 3017.
  • 38
    Chittur S, Parr B, Marcovici G. Inhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic acid and saw palmetto extract. Evid Based Complement Alternat Med 2011; 2011: p. 7 Article ID 985345.
  • 39
    Debruyne F, Boyle P, Calais Da Silva F et al. Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients-PERMAL study subset analysis. Eur Urol 2004; 45: 7739.